Quantification of dopamine D3 receptor mRNA level associated with the development of amphetamine-induced behavioral sensitization in the rat brain

Neuroscience Letters

Volumn 264, Issue 1-3, 1999, Pages 69-72

  Hondo, Hisao ^a   Spitzer, Rebecca H ^a   Grinius, Brone ^a   Richtand, Neil M ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amphetamine; Behavioral sensitization; Dopamine D3 receptor; Ribonuclease protection assay

Indexed keywords

AMPHETAMINE; DOPAMINE 3 RECEPTOR;

ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SENSITIZATION;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CORPUS STRIATUM; IN SITU HYBRIDIZATION; MALE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REFERENCE VALUES; RIBONUCLEASES; RNA, MESSENGER;

EID: 0033515816     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00163-9     Document Type: Article

References (21)

1. Bouthenet M.-L., Souil E., Matres M.-P., Sokoloff P., Giros B., Schwartz J.-C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 564:1991;203-219.
2. Carter C.J., Pycock C.J. Behavioral and biochemical effects of dopamine and noradrenalin depletion within the medial prefrontal cortex. Brain Res. 192:1980;163-169.
3. Costall B., Naylor R.J. Extrapyramidal and mesolimbic involvement with the stereotypic activity of D- and L-amphetamine. Eur. J. Pharmacol. 25:1974;121-129.
4. Creese I., Iversen S.D. The pharmacological and anatomical substrates of amphetamine response in the rat. Brain Res. 83:1975;419-436.
5. De Boer P., Enrico P., Wright J., Wise L.D., Timmerman W., Moor E., Dijkstra D., Wikstrom H.V., Westerink B.H.C. Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels. Brain Res. 758:1997;83-91.
6. Gilbert D.B., Cooper S.J. 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects? Pharmacol. Biochem. Behav. 52:1995;275-280.
7. Jaber M., Cador M., Dumartin B., Normand E., Stinus L., Bloch B. Acute and chronic amphetamine treatments differentially regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience. 65:1995;1041-1050.
8. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 16:1991;223-244.
9. Meador-Woodruff J.H., Little K.Y., Damask S.P., Watson S.J. Effects of cocaine on D3 and D4 receptor expression in the human striatum. Biol. Psychatry. 38:1995;263-266.
10. Merchant K.M., Figur L.M., Evans D.L. Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors. Cereb. Cortex. 6:1996;561-570.
11. Richtand N.M., Kelsoe J.R., Kuczenski R., Segal D.S. Quantification of dopamine D1 and D2 receptor mRNA levels associated with the development of behavioral sensitization in amphetamine treated rats. Neurochem. Int. 31:1997;131-137.
12. Richtand N.M., Kelsoe J.R., Segal D.S., Kuczenski R. Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Mol. Brain Res. 33:1995;97-103.
13. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11:1986;157-198.
14. Segal D.S., Kuczenski R. In vivo microdialysis reveals a diminished amphetamine-induced DA response corresponding to behavioral sensitization produced by repeated amphetamine pretreatment. Brain Res. 571:1992;330-337.
15. Segal, D.S. and Kuczenski, R., Behavioral pharmacology of amphetamine. In A. Cho and D.S. Segal (Eds.), Amphetamine and Its Analogues: Neuropharmacology, Toxicology and Abuse, Academic Press, Orlando, FL, 1994, pp. 81-115.
16. Segal D.M., Moraes C.T., Mash D.C. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Mol. Brain Res. 45:1997;335-339.
17. Sokoloff P., Giros B., Martres M.-P., Bouthenet M.-L., Schwartz J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
18. Tassin J.P., Stinus L., Simon H., Blanc G., Thierry A.M., LeMoal M., Cardo B., Glowinski J. Relationship between the locomotor hyperactivity induced by A10 lesions and the destruction of the fronto-cortical dopaminergic innervation in the rat. Brain Res. 141:1978;267-281.
19. Thorn L., Ashmeade T.E., Storey V.J., Routledge C., Reavill C. Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors. Neuropharmacology. 35:1997;787-792.
20. Waters N., Lofberg L., Haadsma-Svensson S., Svensson K., Sonesson C., Carlsson A. Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J. Neural Transm. Gen. Sect. 98:1994;39-55.
21. Xu M. Unraveling dopamine D3 receptor function in response to psychostimulants using a genetic approach. Ann. N.Y. Acad. Sci. 844:1998;27-39.